Search research articles
Contact Us
Filters
Showing results (1-10 of 79) with videos related to
Page
of 8
Sort By:
Atherosclerosis
|
May 14, 2011
Targeting interleukin-1ß hampers atherosclerosis progression - is there great promise?
Andrea Cignarella
Expert Opinion on Drug Discovery
|
March 14, 2013
Animal and cellular models for hypolipidemic drugs
Andrea Cignarella
Current Atherosclerosis Reports
|
September 20, 2007
Increasingly selective pharmacologic targets in cardiovascular disease
Rodolfo Paoletti, Andrea Cignarella
Hormone Molecular Biology and Clinical Investigation
|
May 12, 2015
Mechanisms of estrogen protection in diabetes and metabolic disease
Andrea Cignarella, Chiara Bolego
Current Atherosclerosis Reports
|
October 4, 2003
Can we stabilize unstable plaque?
Rodolfo Paoletti, Andrea Cignarella
The Journal of Pharmacology and Experimental Therapeutics
|
July 12, 2025
FFAR1/GPR40 agonists: Are new players in type 2 diabetes management on the horizon?
Andrea Cignarella, Samuel Tetteh-Quarshie
Cardiovascular & Hematological Agents in Medicinal Chemistry
|
June 2, 2010
Enhancing endothelial progenitor cell function through selective estrogen receptor modulation: a potential approach to cardiovascular risk reduction
Andrea Cignarella, Gian Paolo Fadini
The Journal of Pharmacology and Experimental Therapeutics
|
July 18, 2024
Mechanistic Chronopharmacology: Preclinical Modeling of an SGLT2 Inhibitor in Preventing Painful Diabetic Neuropathy
Andrea Cignarella, Cristina D Peterson
Cardiovascular Drugs and Therapy
|
December 31, 2003
Impact of statins on novel risk markers
Andrea Cignarella, Chiara Bolego, Rodolfo Paoletti
Trends in Pharmacological Sciences
|
February 9, 2010
Emerging role of estrogen in the control of cardiometabolic disease
Andrea Cignarella, Mario Kratz, Chiara Bolego
Page
of 8
Search research articles
Search
Showing results (1-10 of 79) with videos related to
Sort By:
Page
of 8
Atherosclerosis
|
May 14, 2011
Targeting interleukin-1ß hampers atherosclerosis progression - is there great promise?
Andrea Cignarella
Expert Opinion on Drug Discovery
|
March 14, 2013
Animal and cellular models for hypolipidemic drugs
Andrea Cignarella
Current Atherosclerosis Reports
|
September 20, 2007
Increasingly selective pharmacologic targets in cardiovascular disease
Rodolfo Paoletti, Andrea Cignarella
Hormone Molecular Biology and Clinical Investigation
|
May 12, 2015
Mechanisms of estrogen protection in diabetes and metabolic disease
Andrea Cignarella, Chiara Bolego
Current Atherosclerosis Reports
|
October 4, 2003
Can we stabilize unstable plaque?
Rodolfo Paoletti, Andrea Cignarella
The Journal of Pharmacology and Experimental Therapeutics
|
July 12, 2025
FFAR1/GPR40 agonists: Are new players in type 2 diabetes management on the horizon?
Andrea Cignarella, Samuel Tetteh-Quarshie
Cardiovascular & Hematological Agents in Medicinal Chemistry
|
June 2, 2010
Enhancing endothelial progenitor cell function through selective estrogen receptor modulation: a potential approach to cardiovascular risk reduction
Andrea Cignarella, Gian Paolo Fadini
The Journal of Pharmacology and Experimental Therapeutics
|
July 18, 2024
Mechanistic Chronopharmacology: Preclinical Modeling of an SGLT2 Inhibitor in Preventing Painful Diabetic Neuropathy
Andrea Cignarella, Cristina D Peterson
Cardiovascular Drugs and Therapy
|
December 31, 2003
Impact of statins on novel risk markers
Andrea Cignarella, Chiara Bolego, Rodolfo Paoletti
Trends in Pharmacological Sciences
|
February 9, 2010
Emerging role of estrogen in the control of cardiometabolic disease
Andrea Cignarella, Mario Kratz, Chiara Bolego
Page
of 8